ExpreS2ion, Mucosis, and University of Copenhagen Receive Eurostars Grant

Hørsholm and Copenhagen, Denmark, and Groningen, the Netherlands, September 25, 2012 / B3C newswire / – Biotech com­pa­nies ExpreS2ion Biotechnologies and Mucosis, along with University of Copenhagen today announced that they have been award­ed a Eurostars(TM) grant with a total bud­get of over €1 mil­lion for the pre-clin­i­cal devel­op­ment of an inno­v­a­tive pla­cen­tal malar­ia vac­cine. This col­lab­o­ra­tion will apply nov­el vac­cine tech­nolo­gies devel­oped at Mucosis and ExpreS2ion to a malar­ia anti­gen devel­oped at University of Copenhagen in a project fund­ed by The Danish National Advanced Technology Foundation. This vac­cine devel­op­ment pro­gram aims to pro­vide women in high-risk areas life­long pro­tec­tion against malar­ia infec­tion.
Thomas Johnston, CEO of Mucosis, com­ment­ed: “This Eurostars(TM) fund­ed col­lab­o­ra­tion will lever­age the strengths of our Mimopath mucos­al vac­cine plat­form in com­bi­na­tion with the con­tri­bu­tions of our two pres­ti­gious part­ners in a high-bur­den dis­ease area. We see this oppor­tu­ni­ty as a fur­ther val­i­da­tion of our plat­form and its poten­tial to com­bat the most dif­fi­cult of infec­tious dis­eases.”
Dr. Charlotte Dyring, CEO of ExpreS2ion, said: “We are excit­ed that we have secured this grant and that we will be col­lab­o­rat­ing with Mucosis and their inno­v­a­tive vac­cine deliv­ery approach­es, and with the team at UCPH that has dis­cov­ered and pro­gressed the new promis­ing pla­cen­tal malar­ia vac­cine anti­gen. This col­lab­o­ra­tion will allow us to apply gly­co­sy­la­tion engi­neer­ing to the ExpreS2 plat­form, thus widen­ing the poten­tial of this effi­cient plat­form for pro­duc­tion of recom­bi­nant pro­teins. The con­sor­tium mem­bers have spe­cif­ic com­ple­men­tary know-how and exper­tise that ensure an effi­cient devel­op­ment path in address­ing a sub­stan­tial glob­al health need.”
Dr. Ali Salanti, Associate Professor University of Copenhagen, said: “Vaccines are one of the most effi­cient health inter­ven­tions; how­ev­er devel­op­ment of a malar­ia vac­cine remains a sub­stan­tial chal­lenge. Furthermore, a malar­ia vac­cine to pro­tect preg­nant women from malar­ia would ide­al­ly offer long last­ing pro­tec­tion, and con­ven­tion­al vac­cine meth­ods so far do not deliv­er this. In this new col­lab­o­ra­tion we will have the oppor­tu­ni­ty to apply nov­el vac­cine tech­nolo­gies devel­oped at Mucosis and Expres2ion to our malar­ia vac­cine anti­gen devel­oped at University of Copenhagen, with the aim to devel­op such a vac­cine that can offer women long term pro­tec­tion against malar­ia.”

Leave a Reply

Your email address will not be published. Required fields are marked *